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Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) 
Investigators*
Summary
Background—Reoperation rates are high after surgery for hip fractures. We investigated the 
effect of a sliding hip screw versus cancellous screws on the risk of reoperation and other key 
outcomes.
Methods—For this international, multicentre, allocation concealed randomised controlled trial, 
we enrolled patients aged 50 years or older with a low-energy hip fracture requiring fracture 
fixation from 81 clinical centres in eight countries. Patients were assigned by minimisation with a 
centralised computer system to receive a single large-diameter screw with a side-plate (sliding hip 
screw) or the present standard of care, multiple small-diameter cancellous screws. Surgeons and 
patients were not blinded but the data analyst, while doing the analyses, remained blinded to 
treatment groups. The primary outcome was hip reoperation within 24 months after initial surgery 
to promote fracture healing, relieve pain, treat infection, or improve function. Analyses followed 
the intention-to-treat principle. This study was registered with ClinicalTrials.gov, number 
NCT00761813.
Findings—Between March 3, 2008, and March 31, 2014, we randomly assigned 1108 patients to 
receive a sliding hip screw (n=557) or cancellous screws (n=551). Reoperations within 24 months 
did not differ by type of surgical fixation in those included in the primary analysis: 107 (20%) of 
542 patients in the sliding hip screw group versus 117 (22%) of 537 patients in the cancellous 
screws group (hazard ratio [HR] 0.83, 95% CI 0.63–1.09; p=0.18). Avascular necrosis was more 
common in the sliding hip screw group than in the cancellous screws group (50 patients [9%] vs 
28 patients [5%]; HR 1.91, 1.06–3.44; p=0.0319). However, no significant difference was found 
between the number of medically related adverse events between groups (p=0.82; appendix); these 
events included pulmonary embolism (two patients [<1%] vs four [1%] patients; p=0.41) and 
sepsis (seven [1%] vs six [1%]; p=0.79).
Interpretation—In terms of reoperation rates the sliding hip screw shows no advantage, but 
some groups of patients (smokers and those with displaced or base of neck fractures) might do 
better with a sliding hip screw than with cancellous screws.
Funding—National Institutes of Health, Canadian Institutes of Health Research, Stichting 
NutsOhra, Netherlands Organisation for Health Research and Development, Physicians’ Services 
Incorporated.
Introduction
Worldwide, 4.5 million people per year become disabled after sustaining a hip fracture, with 
the number living with disability due to hip fracture expected to increase to 21 million in the 
next 40 years.1,2 Despite surgical intervention, the need for reoperation remains high (10.0–
48.8%), has remained largely unchanged in the past 30 years,3,4 and is associated with 
substantial morbidity, mortality, and costs.5 The high proportion of reoperations has 
generated controversy about the optimum approach for fixing femoral neck fractures.6
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Biomechanical and laboratory studies7 suggest that although a single large screw at a fixed 
angle with a side-plate (ie, a sliding hip screw) provides greater biomechanical stability, 
especially in displaced and unstable fracture types, multiple cancellous screws, which is the 
present standard of care, are less invasive and better preserve blood supply. Previous small 
trials6 did not find a difference in the effect of the two fixation approaches on outcomes 
important to patients, particularly reoperations, leaving uncertainty among surgeons about 
the optimum approach for fixing femoral neck fractures.
We did the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) 
trial to examine the effect of a sliding hip screw versus cancellous screws on the risk of 
reoperation and other key outcomes during 24 months.
Methods
Study design and participants
FAITH was an international, multicentre, allocation concealed, randomised controlled trial 
assessing the effects of a sliding hip screw versus cancellous screws on reoperation rates 
over a 24 month follow-up in patients with a low-energy femoral neck fracture. A previous 
report8 details the trial objectives and methods. All participating centres obtained ethics 
approval.
We enrolled patients with a low-energy fracture of the hip requiring fracture fixation across 
81 clinical centres in the USA, Canada, Australia, the Netherlands, Norway, Germany, the 
UK, and India. Eligible patients were those aged 50 years or older with a low-energy 
femoral neck fracture requiring operative fixation. Complete eligibility criteria are provided 
in the appendix. All patients provided written informed consent.
Randomisation and masking
Patients were randomly assigned by minimisation to receive a sliding hip screw or 
cancellous screws, with a centralised computer system to ensure allocation concealment and 
balanced prognosis between intervention groups for fracture displacement, age, prefracture 
living status, prefracture function, American Society for Anesthesiologists class, and centre.
9 The study computer programmer generated the minimisation algorithm. Local research 
personnel at each site performed randomisation by minimisation using the centralised 
computer system. Surgeons and patients were not masked but the data analyst, while doing 
the analyses, remained masked to treatment groups.
Procedures
Participants allocated to the sliding hip screw group received a single large-diameter (8.0 
mm), partly threaded screw affixed to the proximal femur with a side plate (with a minimum 
of two holes and a maximum of four holes) and no supplemental fixation. Patients allocated 
to the cancellous screws group received multiple threaded screws, with a minimum of two 
screws and diameter of 6.5 mm. All participating surgeons had done at least 25 hip fracture 
fixation procedures during their career, and at least five fracture fixation procedures in the 
year before participation.
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Surgeons chose the manufacturer, the reduction technique, whether to do a capsulotomy or 
aspiration of intracapsular haematoma, and the final screw position; injectable bone 
substitutes were not permitted. The protocol specified perioperative antibiotics, thrombo-
prophylaxis, and weight-bearing regimens, but left to the surgeons’ discretion patient 
positioning, fracture reduction, and surgical exposure in the operating room. We provided 
surgeons with specific criteria for acceptability of postfixation radiographic fracture 
alignment.
Participants returned for follow-up at 1 and 10 weeks, and at 6, 9, 12, 18, and 24 months 
after surgery. Additional details of the trial intervention and standardisation of perioperative 
care, surgeon expertise, and the follow-up processes are provided in the appendix.
Outcomes
The primary endpoint was reoperation, defined as surgery that occurred subsequent to the 
initial procedure and within 24 months to promote fracture healing, relieve pain, treat 
infection, or improve function. An independent Central Adjudication Committee, 
adjudicated all primary and key secondary outcomes (mortality, fracture healing, and 
fracture complications, including avascular necrosis, non-union, implant failure, and 
infections). Health-related quality of life was measured by the Short Form-12, the EuroQol-5 
Dimensions, and the Western Ontario and McMaster Universities Arthritis Index. Details of 
the primary outcomes, secondary outcomes, and adjudication processes are provided in the 
appendix.
All adverse events were reported to local ethics boards as per local requirements. An 
independent Data and Safety Monitoring Board monitored the safety of the trial and 
reviewed all serious adverse events.
Statistical analysis
The sample size calculation was based on the primary outcome of hip reoperation and used 
the Cox proportional hazards model as described by Collett.10 Originally we determined that 
enrolment of 1500 patients would give the trial 81.5% power to detect a hazard ratio (HR) of 
0.75 in the sliding hip screw group, at a two-sided alpha level of 0.05, on the assumption that 
the percentage of the primary outcome in the cancellous screws group would be 25% 
(appendix).8
The Data and Safety Monitoring Board met in January, 2014, after 589 patients completed 
follow-up. They provided the Steering Committee with overall event rates to inform a 
revised power analysis that balanced feasibility of completing recruitment within an 
acceptable timeframe and supporting plausible hypotheses of treatment effect and baseline 
event rates. On the basis of the number of events in the first 589 patients, we estimated a 24 
month primary event rate of 27.2%; a 24 month mortality rate of 18.2%; a 24 month 5.9% 
incidence of loss to follow-up; and a combined 6.8% crossover rate. With these estimates, a 
sample size of 500 patients per group would provide 95.7% power to detect a relative risk 
reduction of 35%. On the basis of these data, we targeted a sample size of 1100 patients. A 
methods paper8 published previously presents details of the sample size calculations and 
rationale.
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Analyses followed the intention-to-treat principle and included all patients in the groups to 
which they were randomly assigned. Patients who did not complete the 24 month follow-up 
were censored at their last documented follow-up. After assessment of its appropriateness, 
the primary analysis used a Cox proportional hazards model stratified by clinical site. We 
report the treatment effects as HRs and 95% CIs. An analysis adjusting for death as a 
competing risk provided a sensitivity analysis. The analyses of treatment effect on fracture-
related adverse events and mortality also relied on a stratified Cox proportional hazards 
regression.
We analysed the health-related quality-of-life outcomes at 24 months using a multiple linear 
regression model with treatment and pre-injury quality of life (obtained at 1 week) included 
as independent variables. Results are reported as mean differences with corresponding 95% 
CIs and p values.
At the trial onset we specified a single a-priori subgroup analysis investigating fracture 
displacement as a possible effect modifier, anticipating that sliding hip screw relative to 
multiple cancellous screws would do better in displaced versus non-displaced fractures.10 At 
the completion of the trial, but before unblinding and as described in our statistical analysis 
plan, we prespecified an additional five subgroup analyses that investigated a possible effect 
modification by location of fracture line, body-mass index, verticality of the fracture line, 
smoking status, and quality of fracture reduction. We did an additional post-hoc subgroup 
analysis assessing the possible effect modification of patient age. We did tests of interaction 
for individual subgroups and, when three provide significant results, an analysis that 
simultaneously considered all their possible interactions. We used multiple criteria to 
consider the credibility of any possible subgroup effects.11,12 Details for postulated 
subgroup effects are provided in the appendix. All analyses were done with SAS version 9.4 
(Cary, NC, USA). This study was registered with ClinicalTrials.gov, number NCT00761813.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Between March 3, 2008, and March 31, 2014, we randomly assigned 1108 patients to 
receive a sliding hip screw (n=557) or cancellous screws (n=551; figure 1). The 
Adjudication Committee determined that 29 patients were ineligible, most as a result of an 
ineligible fracture type, or surgical treatment delayed beyond 4 days in patients with 
displaced fractures, leaving 1079 patients in the final analyses. The rationale for post-
randomisation exclusions is in the appendix. Of the 923 patients alive at 24 months, we 
achieved 24 month follow-up for 844 (91%; figure 1, appendix). The mean length of follow-
up was 633 days (SD 208).
Typical patients were women aged 70–80 years who had fallen and sustained an isolated, 
non-displaced fracture of the femoral neck; group characteristics were similar (tables 1, 2). 
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Acceptable reduction (open and closed) was achieved in nearly all patients (99%; table 2). In 
549 patients with displaced fractures, acceptable reduction was achieved in 545 (99%). 
Those who underwent cancellous screw fixation typically received three parallel screws in a 
triangular configuration, whereas those in the sliding hip screw group received a single large 
compression screw in the centre–centre head position with a two-hole side plate; 
perioperative management was similar across groups (tables 1, 2; appendix).
The overall crossover was 2.0%, with significant differential crossovers between treatment 
groups (p=0.03). Surgeon compliance for the initial allocated surgical fixation approach was 
97% (n=16) for sliding hip screw and 99% (n=6) for cancellous screws (appendix).
The primary study endpoint, hip reoperation within 24 months, did not differ by type of 
surgical fixation (table 3, figure 2). A competing risk sensitivity analysis adjusting for death 
yielded similar results for the primary endpoint (0.89, 0.69–1.16).
Number of deaths did not differ between groups (table 3). Avascular necrosis occurred in 
about 7% of patients overall and differed by fixation group, with more occurring in the 
sliding hip screw group than in the cancellous screws group. Of these, 54 (69%) patients 
required an operation: 38 patients in the sliding hip screw group and 16 in the cancellous 
screws group (p=0.002). Implant removal took place significantly less frequently in the 
sliding hip screw group than in the cancellous screws group (table 3). Implant exchange to 
revise to another internal fixation also occurred less frequently with sliding hip screws than 
cancellous screws (table 3). Alternatively, implant exchange to a total hip replacement was 
more common in the sliding hip group.
Non-unions, implant failures, infections, fracture shortening, and fracture healing did not 
differ by surgical fixation approach (table 3). Health-related quality of life did not differ 
between patients assigned to sliding hip screws and multiple cancellous screws at 12 month 
and 24 month follow-up (table 4).
Medically related adverse events did not differ by treatment group (p=0.82; table 5).
Subgroup analyses favoured sliding hip screw in patients with displaced fractures, fractures 
at the base of the femoral neck, and in those who were current smokers (appendix, figure 3). 
Only smoking status remained significant when these three subgroups were entered into a 
single analysis (figure 3). Sliding hip screw was superior in current smokers, but not in 
former or non-smokers (figure 3, appendix).
Discussion
We have shown a similar risk of hip reoperation in patients with low-energy femoral neck 
fractures randomly assigned to sliding hip screw as in those assigned to cancellous screws at 
24 months; avascular necrosis occurred more frequently in patients allocated to sliding hip 
screw. Subgroup analyses of low-to-moderate credibility, suggested sliding hip screws 
reduced reoperations in patients with displaced fractures, fractures at the base of the femoral 
neck, and in current smokers.
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Although the frequency of reoperations was similar between the two treatment groups, there 
were differences in the component outcomes of reoperations. Patients in the sliding hip 
screw group, compared with those in the cancellous screws group, had a lower frequency of 
a reoperation for an implant removal and an implant exchange based on an internal fixation 
approach, but had a higher frequency of reoperation for an implant exchange with a total hip 
arthroplasty approach. Patients undergoing total hip arthroplasty after failed internal fixation 
compared with those undergoing primary total hip arthroplasty could be at higher risk of 
complications.19 As such, the number of arthroplasties in the cancellous screws group 
suggests a potential advantage of the treatment over a sliding hip screw. Although the 
decision to choose one approach to implant exchange over another was left to the surgeon’s 
discretion, the choice might also indicate surgeon preference.
Looking separately at possible effect modifiers, displaced versus non-displaced fractures, 
fracture site, and smoking status, interaction p values all reached conventional statistical 
significance, all suggesting benefits of sliding hip screws over cancellous screws in a 
subpopulation of patients (figure 3). All were a-priori hypotheses with a biological rationale 
that led to a correct predicted direction of effect. In particular, the greater biomechanical 
stability of sliding hip screws might offer advantages in fracture with displacement and in 
smokers, who have greater risk of osteoporosis and diminished bone density than do non-
smokers.7,20–23 Sliding hip screws remain the standard of care in patients with inter-
trochanteric fractures, a region in close proximity to the base of the femoral neck,24 
providing a biological rationale for the finding that sliding hip screws reduced reoperations 
in the subgroup of patients with base of femoral neck fractures. Furthermore, the 
displacement hypothesis was originally our sole hypothesis and a minimisation variable.11,12
However, when all three potential effect modifiers were considered together, only smoking 
retained a low, although not extremely low, p value (figure 3). Additionally, we tested 
multiple hypotheses, and did not find similar effects in health-related quality of life. As such, 
in view of all these issues, the apparent subgroup effects have only modest credibility.
Strengths of FAITH include safeguards against risk of bias (concealed randomisation, 
centralised and independent outcome adjudication, blinded analysis of data); high 
compliance with study procedures; broad inclusion criteria with a large number of centres in 
countries with diverse health-care systems; a focus on outcomes of importance to both 
patients and the health-care system (ie, reoperation, health-related quality of life); and 
rigorous investigation of subgroup effects, with due attention to their credibility.11,12
Our study has limitations. Surgeons and patients were not blinded. However, we did 
minimise the associated risk of bias with central and independent, although unblinded, 
radiographic adjudication of the primary endpoint. Furthermore, reoperation is an objective 
endpoint and a major procedure; surgeons will seldom decide to reoperate in the absence of 
a compelling indication. Follow-up at 24 months was less than complete (844 [91%] of 923 
patients who were alive); our success in following up patients was consistent and in most 
cases better than in previous smaller trials.3 Unavoidable heterogeneity related to the 
variables that were not standardised also existed; these variables were patient positioning, 
Page 7



















fracture reduction, surgical exposure, use of operative traction, surgical delay, type of 
anaesthetic, physiotherapy, and rehabilitation programmes.
In relation to previous research, a meta-analysis of small trials suggested a non-significant 
difference in reoperations favouring sliding hip screw (relative risk 0.86, 95% CI 0.70–1.05; 
p=0.13).19 An updated pooled analysis of reoperation including small trials with our FAITH 
results (eight trials, 1913 patients) reported a 95% CI that was narrower than our study’s but 
was still consistent, with no difference between fixation methods (0.91, 0.76–1.08; p=0.27, 
I2=7%).25–31
With respect to avascular necrosis, our results differ importantly from a previous systematic 
review19 of small trials, which suggested that a sliding hip screw, in comparison with 
cancellous screws, might reduce the risk of avascular necrosis. The addition of another small 
trial to a previous meta-analysis results in a significant reduction in the risk of avascular 
necrosis with sliding hip screws (77 events; relative risk 0.64, 95% CI 0.43–0.97; p=0.04, 
I2=0%).19,25
Despite the previous results, increased risk of avascular necrosis from our results has a 
plausible biological rationale. Hip fractures can disrupt the retinacular vessels, which are 
crucial for the vascular supply of the femoral head.32 A randomised trial33 of 104 patients 
with femoral neck fractures using bone scintigraphy showed reduced vascularity in patients 
receiving a sliding hip screw compared with those receiving cancellous screws (35% vs 
11%, p<0.01). Furthermore, suboptimum positioning of large implants, such as sliding hip 
screws, risks damage to the blood supply to the femoral head.34 In terms of the importance 
of avascular necrosis, observational studies have shown that many patients remain 
asymptomatic, with only one in five requiring further surgery.35,36
Our results, in the context of previous results, suggest that the choice of procedure for 
internal fixation is a matter of discretion. Findings favouring cancellous screws were the 
non-significant difference in the likelihood of reoperation between procedures, and the 
higher likelihood of avascular necrosis and subsequent total arthroplasties in patients 
receiving a sliding hip screw. However, our finding of increased avascular necrosis with a 
sliding hip screw, compared with cancellous screws, is inconsistent with other studies and 
did not result in more operations or poorer quality of life in the total population. Moreover, 
findings across all trials remain consistent, with overall decreased reoperations in patients 
receiving a sliding hip screw, and subgroup analyses of low credibility suggesting that 
patients with displaced fractures, smokers, and patients with base of neck fractures might do 
better with a sliding screw than with cancellous screws.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Evidence before this study
We searched the computerised databases Medline and PubMed for randomised clinical 
trials published in English between Jan 1, 1969, and June 1, 2002, using the search terms 
“femoral neck fracture” AND “arthroplasty”, as well as “femoral neck fracture” AND 
“internal fixation”. In addition, bibliographies were searched for relevant studies. We also 
identified additional studies through hand searches of major orthopaedic journals, 
bibliographies of major orthopaedic textbooks, and personal files. Of 140 citations 
initially identified, 14 met all eligibility criteria. Three investigators independently graded 
study quality and abstracted relevant data, including information on revision and 
mortality rates. An international survey of orthopaedic surgeons identified that most 
surgeons preferred to fix femoral neck hip fractures with multiple cancellous screws 
rather than a sliding hip screw. Despite the popularity of cancellous screws for hip 
fracture fixation, biological investigations have suggested that the sliding hip screw is a 
more biomechanically stable construct compared with cancellous screws. Moreover, a 
previous Cochrane meta-analysis of small trials reported a non-significant reduction in 
reoperations with a sliding hip screw compared with multiple cancellous screws (relative 
risk 0.86, 95% CI 0.70–1.05), and that the risk of avascular necrosis with a sliding hip 
screw was significantly reduced. The small sample sizes and resultant imprecise 
estimates, and methodological limitations, of previous work left the issue in doubt.
Added value of this study
Our trial enrolled more than 1000 patients across multiple countries, providing improved 
precision and generalisability to both high-income countries and low-to-middle-income 
countries. Our trial also addresses the dearth of health-related quality-of-life data for 
patients who had surgical fixation for femoral neck fractures.
Implications of all the available evidence
Although our findings, consistent with those of previous randomised controlled trials, did 
not show a difference in the likelihood of reoperation in patients randomly assigned to a 
sliding hip screw versus cancellous screws, health-related quality of life was similar 
across both interventions. However, we did show a significant increase in the likelihood 
of avascular necrosis with a sliding hip screw compared with cancellous screws. 
Nonetheless, this finding is not only inconsistent with previous results, but also did not 
result in an overall increase in reoperations or a decrement in health-related quality of 
life. Moreover, our results raise the possibility that a sliding hip screw, relative to 
cancellous screws, might reduce reoperations in patients with displaced fractures, in 
smokers, and in patients with base of neck fractures.
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Kaplan-Meier curves for reoperation
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Figure 3. Subgroup analyses of surgical fixation primary endpoint (reoperation)
BMI=body-mass index.*Interaction p value for group comparison. †Defined at study start. 
‡Defined at study close (before unblinding).
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Sliding hip screw (n=542) Cancellous screws (n=537) Total (n=1079)
Age (years) 72.2 (12.0) 72.0 (12.3) 72.1 (12.2)
Sex
 Male 212/535 (40%) 210/535 (39%) 422/1070 (39%)
 Female 323/535 (60%) 325/535 (61%) 648/1070 (61%)
Ethnic origin
 Native 1/533 (<1%) 3/535 (1%) 4/1068 (<1%)
 South Asian 65/533 (12%) 65/535 (12%) 130/1068 (12%)
 East Asian 6/533 (1%) 4/535 (1%) 10/1068 (1%)
 Black 22/533 (4%) 18/535 (3%) 40/1068 (4%)
 Hispanic 3/533 (1%) 1/535 (<1%) 4/1068 (<1%)
 White 436/533 (82%) 444/535 (83%) 880/1068 (82%)
Smoking history
 Never smoked 268/533 (50%) 276/532 (52%) 544/1065 (51%)
 Current smoker 101/533 (19%) 100/532 (19%) 201/1065 (19%)
 Former smoker 164/533 (31%) 156/532 (29%) 320/1065 (30%)
Current drugs
 None 170/535 (32%) 179/534 (34%) 349/1069 (33%)
 NSAIDS 86/535 (16%) 64/534 (12%) 150/1069 (14%)
 General cardiac 167/535 (31%) 167/534 (31%) 334/1069 (31%)
 Opioid analgesics 43/535 (8%) 56/534 (10%) 99/1069 (9%)
 Pulmonary drugs 58/535 (11%) 69/534 (13%) 127/1069 (12%)
 Anti-hypertension drugs 244/535 (46%) 252/534 (47%) 496/1069 (46%)
 Osteoporosis drugs 67/535 (13%) 73/534 (14%) 140/1069 (13%)
BMI
 Underweight (BMI <18.5) 37/530 (7%) 33/528 (6%) 70/1058 (7%)
 Normal weight (18.5–24.9) 276/530 (52%) 300/528 (57%) 576/1058 (54%)
 Overweight (25–29.9) 159/530 (30%) 148/528 (28%) 307/1058 (29%)
 Obese (30–39.9) 58/530 (11%) 47/528 (9%) 105/1058 (10%)
Fractured hip N=535 N=535 N=1070
 Left 280/535 (52%) 281/535 (53%) 561/1070 (52%)
 Right 255/535 (48%) 254/535 (47%) 509/1070 (48%)
Mechanism of injury
 Fall 515/533 (97%) 521/534 (98%) 1036/1067 (97%)
 Spontaneous 13/533 (2%) 6/534 (1%) 19/1067 (2%)
 Other low energy trauma 5/533 (1%) 7/534 (1%) 12/1067 (1%)




















Sliding hip screw (n=542) Cancellous screws (n=537) Total (n=1079)
History of surgery to affected hip
 Yes 3/535 (1%) 0/535 (0%) 3/1070 (<1%)
 No 532/535 (99%) 535/535 (100%) 1067/1070 (100%)
Additional injuries
 Yes 67/535 (13%) 72/535 (13%) 139/1070 (13%)
 No 468/535 (87%) 463/535 (87%) 931/1070 (87%)
Data are mean (SD) or n/N (%). For some subgroups, the numbers of patients analysed are smaller than that of the overall group number because 
data are missing for some variables. NSAIDS=non-steroidal anti-inflammatory drugs. BMI=body-mass index.






















Sliding hip screw (n=542) Cancellous screws (n=537) Total (n=1079)
Level of the fracture line
 Subcapital 331/535 (62%) 351/536 (65%) 682/1071 (64%)
 Midcervical 159/535 (30%) 154/536 (29%) 313/1071 (29%)
 Basal 45/535 (8%) 31/536 (6%) 76/1071 (7%)
Garden classification13
Undisplaced 360/542 (66%) 369/537 (69%) 729/1079 (68%)
 Garden I 257/542 (47%) 277/537 (52%) 534/1079 (49%)
 Garden II 99/542 (18%) 92/537 (17%) 191/1079 (18%)
Displaced 182/542 (34%) 168/537 (31%) 350/1079 (32%)
 Garden III 121/542 (22%) 128/537 (24%) 249/1079 (23%)
 Garden IV 58/542 (11%) 39/537 (7%) 97/1079 (9%)
Pauwel’s classification14,15
Type I 59/535 (11%) 59/536 (11%) 118/1071 (11%)
Type II 398/535 (74%) 394/536 (74%) 792/1071 (74%)
Type III 78/535 (15%) 83/536 (15%) 161/1071 (15%)
Preoperative traction
Skin traction 75/535 (14%) 76/535 (14%) 151/1070 (14%)
Skeletal traction 7/535 (1%) 3/535 (1%) 10/1070 (1%)
None 453/535 (85%) 456/535 (85%) 909/1070 (85%)
Type of reduction
None 210/531 (40%) 237/528 (45%) 447/1059 (42%)
Closed 287/531 (54%) 277/528 (52%) 564/1059 (53%)
 Acceptable 286/287 (100%) 275/277 (99%) 561/564 (99%)
 Unacceptable 1/287 (<1%) 2/277 (1%) 3/564 (1%)
Open 34/531 (6%) 14/528 (3%) 48/1059 (5%)
 Acceptable 32/34 (94%) 14/14 (100%) 46/48 (96%)
 Unacceptable 2/34 (6%) 0/14 (0%) 2/48 (4%)
Data are n/N (%).





















Study outcomes by treatment group
Overall (n=1079)
Sliding hip 
screw (n=542) Cancellous screws (n=537)
Hazard ratio 
(95% CI) p value
Reoperation
 Any reoperation 224 (21%) 107 (20%) 117 (22%) 0.83 (0.63–1.09) 0.18
 Implant removal 74 (7%) 25 (5%) 49 (9%) 0.42 (0.25–0.70) 0.0009
 Implant exchange: total hip 
arthroplasty
104 (10%) 64 (12%) 40 (7%) 1.51 (1.00–2.27) 0.0494
 Implant exchange: hemiarthroplasty 55 (5%) 26 (5%) 29 (5%) 0.89 (0.52–1.51) 0.66
 Implant exchange: internal 16 (1%) 2 (<1%) 14 (3%) 0.14 (0.03–0.62) 0.0024
Fixation
 Implant exchange: spacer 3 (<1%) 1 (<1%) 2 (<1%) 0.50 (0.05–5.45) 0.56
 Soft tissue procedure 6 (1%) 4 (1%) 2 (<1%) 1.98 (0.36–10.77) 0.42
 Proximal femoral osteotomy 1 (<1%) 1 (<1%) 1 (<1%) 0.99 (0.06–15.80) 0.99
Avascular necrosis 78 (7%) 50 (9%) 28 (5%) 1.91 (1.06–3.44) 0.0319
Non-union 66 (6%) 33 (6%) 33 (6%) 0.92 (0.48–1.75) 0.80
Implant failure 87 (8%) 42 (8%) 45 (8%) 0.95 (0.61–1.48) 0.81
Infection
 Any infection 19 (2%) 10 (2%) 9 (2%) 1.10 (0.45–2.69) 0.83
 Superficial infection 8 (1%) 4 (1%) 4 (1%) 0.99 (0.25–3.94) 0.99
 Deep infection 11 (1%) 6 (1%) 5 (1%) 1.19 (0.37–3.87) 0.77
Fracture healing*
 Healed by month 24 532/795 (67%) 262/398 (66%) 270/397 (68%) .. 0.71
 Not healed by month 24 3/795 (<1%) 2/398 (1%) 1/397 (<1%) ..
 Not healed at time of last visit 260/795 (33%) 134/398 (34%) 126/397 (32%) ..
Fracture shortening >5 mm (n=532)† 146/532 (27%) 69/262 (26%) 77/270 (29%) 0.92 (0.70–1.22) 0.57
Mortality 156 (14%) 73 (13%) 83 (15%) 0.81 (0.58–1.12) 0.20
Data are n (%). Relative risk was calculated where the total number of events is less than 50.
*
795 patients were included in the fracture healing analysis. 284 patients did not have radiograph available for fracture healing adjudication, and 
therefore were not included in the denominator.
†
532 patients were included in the shortening analysis on the basis of the number of healed fractures with shortening data.





















Health-related quality of life by treatment groups without interaction of displacement
Sliding hip screw Cancellous screws n Adjusted mean difference (95% CI) p value for differences 
between groups
n Mean (SD) n Mean (SD)
12 months
SF-12 PCS16 235 40.8 (11.1) 224 41.9 (10.7) 435 −0.02 (−1.79 to 1.74) 0.98
WOMAC17 240 44.69 (19.08) 226 41.32 (16.73) 438 1.98 (−1.13 to 5.09) 0.21
EQ-5D Index18 249 0.77 (0.20) 238 0.80 (0.17) 460 −0.02 (−0.05 to 0.02) 0.33
24 months
SF-12 PCS16 207 41.6 (10.9) 181 41.4 (11.8) 358 0.50 (−1.61 to 2.61) 0.64
WOMAC17 205 40.97 (16.33) 183 39.75 (17.09) 355 0.35 (−3.03 to 3.74) 0.84
EQ-5D Index18 232 0.79 (0.19) 207 0.80 (0.19) 406 −0.01 (−0.04 to 0.02) 0.51
SF-12 PCS=Short Form-12. PCS=Physical component score. WOMAC=Western Ontario and McMaster Universities Arthritis Index. 
EQ-5D=EuroQol-5 Dimensions.





















Medically related adverse events
Sliding hip screw (n=542) Cancellous screws (n=537) p value
Pneumonia 23 (4%) 24 (4%) 0.86
Deep vein thrombosis 6 (1%) 8 (1%) 0.58
Pulmonary embolism 2 (<1%) 4 (1%) 0.41
Sepsis 7 (1%) 6 (1%) 0.79
Myocardial infarction 9 (2%) 7 (1%) 0.63
Congestive heart failure 7 (1%) 6 (1%) 0.79
Other cardiovascular adverse events 43 (8%) 43 (8%) 0.96
Pulmonary 24 (4%) 16 (3%) 0.21
Decreased cognitive ability 14 (3%) 23 (4%) 0.12
Neurological 10 (2%) 10 (2%) 0.98
Digestive 17 (3%) 18 (3%) 0.84
Blood 17 (3%) 12 (2%) 0.36
Renal 8 (1%) 10 (2%) 0.62
Urinary 23 (4%) 20 (4%) 0.66
Multiple organ complications 3 (1%) 0 0.08
Total 122 (23%) 124 (23%) 0.82
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